Related Experiment Video

Updated: Jan 4, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.5K

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma

Sergiu Pasca1, Ciprian Tomuleasa1,2,3, Patric Teodorescu1,2

  • 1Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Frontiers in Oncology
|November 12, 2019
PubMed

Insights

Patients with multiple myeloma harboring KRAS, NRAS, or BRAF mutations may benefit from immunotherapy and MAPK pathway inhibitors due to increased neo-antigens and T-cell activation. These genetic alterations suggest potential therapeutic strategies for this patient subgroup.

Area of Science:

  • Oncology
  • Genetics
  • Immunology

Background:

  • Multiple myeloma is characterized by chromosomal translocations and single nucleotide mutations.
  • Mutations frequently affect the mitogen-activated protein kinase (MAPK) pathway, including KRAS, NRAS, and BRAF genes.

Purpose of the Study:

  • To investigate the potential therapeutic benefits of immunotherapy and MAPK pathway inhibitors in multiple myeloma patients with specific genetic mutations.
  • To hypothesize that KRAS/NRAS/BRAF mutations, associated with a higher mutation burden, may predict response to checkpoint inhibitors and IMiD therapy.

Main Methods:

  • This study is based on a hypothesis derived from existing mutational profile data in multiple myeloma.
  • Analysis of the association between KRAS/NRAS/BRAF mutations and potential therapeutic targets.

Main Results:

  • KRAS/NRAS/BRAF mutations are linked to a higher number of mutations per patient, suggesting increased neo-antigen presentation.
  • This mutational profile may enhance the efficacy of immune checkpoint inhibitors and IMiD therapy due to T-cell activation.

Conclusions:

  • Multiple myeloma patients with KRAS/NRAS/BRAF mutations represent a subgroup that could potentially benefit from immunotherapy.
  • Targeting the MAPK pathway, directly or downstream (MEK1/2, ERK1/2), is a promising therapeutic strategy for this patient population.
Keywords:
BRAFKRASNRASmultiple myelomatherapeutics

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.6K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.2K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K